Literature DB >> 21095413

Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).

Claus G Roehrborn1.   

Abstract

Male lower urinary tract symptoms, benign prostatic hyperplasia, enlargement of the prostate, and bladder outlet obstruction are common among aging men and will increase in socioeconomic and medical importance at a time of increased life expectancy and aging of the baby boomer generation. This article reviews the epidemiology, management, and therapeutic options for these conditions. In patients bothered by moderate to severe symptoms, providers can make educated and differential choices between several classes of drugs, alone or in combination, to treat effectively and improve the symptoms in most men. Despite the efficacy of medical therapy, there will be patients who require referral to a urologist either early, to rule out prostate cancer and other conditions, or later, after initial medical therapy and lifestyle management has failed. Perhaps as many as 30% of patients fail to achieve sufficient symptom improvement with medication, lifestyle adjustment, and fluid management, and may require more invasive or surgical treatment options.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21095413     DOI: 10.1016/j.mcna.2010.08.013

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  64 in total

1.  Impact of partial urethral obstruction on bladder function: time-dependent changes and functional correlates of altered expression of Ca²⁺ signaling regulators.

Authors:  David Burmeister; Tamer AbouShwareb; Ralph D'Agostino; Karl-Erik Andersson; George J Christ
Journal:  Am J Physiol Renal Physiol       Date:  2012-03-21

2.  Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: profile report.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2011-10-01       Impact factor: 3.923

Review 3.  Urolift: a New Face of Minimally Invasive Surgical Technique for Benign Prostatic Hyperplasia?

Authors:  Johnson F Tsui; Christopher M Dixon
Journal:  Curr Urol Rep       Date:  2016-09       Impact factor: 3.092

4.  Effects of low-frequency ultrasound combined with microbubbles on benign prostate hyperplasia.

Authors:  Shao-Ling Yang; Ke-Qiang Tang; Wen-Kun Bai; E Shen; Yi-Wen Zhao; Yan-Duan Lin; Shu-Liang Nan; Hu Bing
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

5.  Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway.

Authors:  Jean-Nicolas Cornu; Etienne Audet-Walsh; Sarah Drouin; Pierre Bigot; Antoine Valeri; Georges Fournier; Abdel-Rahmène Azzouzi; Morgan Roupret; Luc Cormier; Stephen Chanock; Chantal Guillemette; Olivier Cussenot; Eric Lévesque; Géraldine Cancel-Tassin
Journal:  World J Urol       Date:  2016-06-08       Impact factor: 4.226

Review 6.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

7.  [Intraprostatic injection therapy in patients with benign prostatic syndrome].

Authors:  T Bschleipfer; T Bach; C Gratzke; S Madersbacher; M Oelke
Journal:  Urologe A       Date:  2013-03       Impact factor: 0.639

8.  Clinical study on Kangquan Recipe (康泉方) for benign prostatic hyperplasia patients: a randomized controlled trial.

Authors:  Yuan-peng Huang; Yan-hui Wen; Geng-hui Wu; Zhen-feng Hong; Shang-wen Xu; A-xiang Peng
Journal:  Chin J Integr Med       Date:  2014-11-27       Impact factor: 1.978

9.  Targeting a fibrotic bottleneck may provide an opening in the treatment of LUTS.

Authors:  William A Ricke; Reginald C Bruskewitz; Teresa T Liu
Journal:  Am J Physiol Renal Physiol       Date:  2019-03-13

Review 10.  Combination pharmacological therapies for the management of benign prostatic hyperplasia.

Authors:  Seth A Cohen; J Kellogg Parsons
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.